You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. System for automatic classification of rodent vocalizations

    SBC: BIOSPEECH INC            Topic: 101

    DESCRIPTION provided by applicant Depression dementia schizophrenia substance abuse developmental disorders and speech related disabilities can feature impairments in the ability to express emotions Development of treatments for these impairments presents a formidable challenge In this regard several researchers who study rodent models of mental illness have more recently focused upon t ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Novel S. aureus Antibiotics with Reduced Resistance Susceptibility

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Widespread antibiotic use has accelerated S aureus resistance to almost all marketed antibiotic classes including beta lactams fluoroquinolones macrolides aminoglycosides tetracyclines as well as the newer linezolid and daptomycin Methicillin resistant S aureus MRSA is an increasing public health threat with deaths from MRSA infections already compar ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Development of broad spectrum Hepatitis C Virus NS3/4A protease inhibitors

    SBC: NOVALEX THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This is a collaborative proposal to develop inhibitors with reduced susceptibility to resistance and improved genotype spectrum of activity against the NS A protease of the Hepatitis C virus HCV Over three percent of the worldandapos s population is infected with the hepatitis C virus HCV Unfortunately the current best treatment is still quite challeng ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Recycling Rare Earth Metals from Nickel Metal Hydride Batteries

    SBC: ONTO TECHNOLOGY, LLC            Topic: C

    This Phase I Small Business Innovation Research Project develops methods of recycling rare earth alloys from used nickel metal hydride batteries. Alloys of rare earth metal, nickel and other metals provide functional hydride storage materials that are critical to the operation of nickel metal hydride batteries and their applications. The current fleet of hybrid electric vehicles relies upon nick ...

    SBIR Phase I 2012 Environmental Protection Agency
  5. Preconcentration Technoloogy for Infrared Analysis of Organophosphates in Water

    SBC: Orono Spectral Solutions Inc.            Topic: I

    Organophosphates cannot currently be analyzed in the field using existing technologies, due to insufficient sensitivity of currently fielded instruments. This inability reduces the number of analyses that a government agency can perform on a water supply to ensure its safety to humans and the environment. The objective of this Phase I effort is to design a novel strategy that preconcentrates org ...

    SBIR Phase I 2012 Environmental Protection Agency
  6. A 10 Kilowatt, Rankine Cycle Agricultural Waste to Energy Conversion Module Utilizing Ultra Micro Turbo-Alternators

    SBC: Fluidic microControls, Inc.            Topic: H

    Current anaerobic digester systems are designed for capturing energy from waste from large heads of farm animals. GHD, Inc., a leading manufacturer of anaerobic digesters, has stated that a minimum dairy heard size for economical implementation of a biogas system as 800 cows. These require turbine or diesel generator sets of 100 Kilowatt size and larger, a limiting factor in economically scaling ...

    SBIR Phase I 2012 Environmental Protection Agency
  7. Advanced Plate Osteosynthesis Technology to Promote Healing of Bone Fractures

    SBC: Apex Biomedical Company, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Each year, over 6 million fractures are treated in the United States at a cost in excess of 13 billion. Between 5-8% of these fractures experience complications, particularly in the steadily increasing population withosteoporosis. By providing better fixation in osteoporotic bone, locked plating technology has rapidly transformed fracture treatment with bone ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Mobile Phone Application to Increase Tobacco Cessation Medication Adherence

    SBC: InterVision Media            Topic: NCI

    DESCRIPTION (provided by applicant): Tobacco is the leading cause of preventable disease and death in the U.S. Although effective tobacco cessation medications exist, the impact of these medications is diminished by lack of adherence by the patient. Basedon our team's expertise in the use of technology to improve evidence-based treatment of tobacco dependence and improving asthma medication a ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Iron functionalized silica as oral phosphate binder to treat hyperphosphatemia

    SBC: PDX PHARMACEUTICALS, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Hyperphosphatemia is universal to end stage chronic kidney disease patients and a majority of dialysis patients totaling of 400,000 in the US and 2 million worldwide. Current oral phosphate binders to treat hyperphosphatemia still have many drawbacks, including a high risk of calcification, high costs ( 2100- 6500 per patient a year), low-to-moderate efficacy, ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Novel drug VS-105 for treatment of diabetic nephropathy

    SBC: Vidasym, Inc            Topic: NIDDK

    DESCRIPTION (provided by applicant): Twenty-six million people in America have chronic kidney disease (CKD). Diabetes is by far the leading cause of CKD (diabetic nephropathy), accounting for 44% of new cases of dialysis (in 2005). Current treatments including ACE inhibitors for CKD patients mainly focus on managing symptoms and disease complications. Despite the various treatments available, the ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government